Skip to main content
Clinical Trials/CTRI/2024/03/064117
CTRI/2024/03/064117
Not yet recruiting
Phase 2

Assessment of safety and efficacy of Nutraceutical supplements/AYUSH medicines in healthy human volunteers. - NI

HERBOLAB INDIA PVT LTD0 sites0 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
HERBOLAB INDIA PVT LTD
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
HERBOLAB INDIA PVT LTD

Eligibility Criteria

Inclusion Criteria

  • 1\. Healthy male and female human trial participants aged between 18 and 60 years (both inclusive);2\. Female trial participants must have a negative urine pregnancy test prior to the housing;3\. Male and females agreeing to use the contraceptive pill or abstinence as a method of contraception during and 07 days after completion of the study;4\. Trial participants with a BMI between 18\.50\-29\.90 kg per m2 and body mass, not less than 50\.00 kg;5\. Trial participants in normal health as determined by personal medical history, clinical examination including vital signs, and clinically acceptable results of laboratory examinations (including serological tests).

Exclusion Criteria

  • 1\.Incapable of understanding the informed consent information;
  • 2\.Clinically significant medical condition, such as, but not limited to,
  • cardiovascular, neurological, psychiatric, pulmonary, renal,
  • immunological, endocrine (including uncontrolled diabetes or thyroid
  • disease), or uncontrolled haematological abnormalities;
  • 3\.History or presence of alcoholism or drug abuse;
  • 4\.History or presence of cancer;
  • 5\.Use of any prescribed medication (including herbal remedies)
  • during the two weeks before the start of the study or OTC medicinalproducts (including herbal remedies) during the week before study initiation and throughout the study;
  • 6\.Major illness during the 90 days before screening;

Outcomes

Primary Outcomes

Not specified

Similar Trials